The objective of this study is to evaluate the safety and efficacy as assessed by the Alzheimers Disease Assessment Scale-cognitive subscale 13-item (ADAS-cog-13) of two doses of MT-4666 or placebo administered daily for 24 weeks to subjects with mild to moderate Alzheimer's disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
450
Unnamed facility
Kanto, Japan
Change from baseline in ADAS-cog-13
Time frame: Baseline and Week 24
Change from baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)
Time frame: Baseline and Week 24
Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
Time frame: Baseline and Week 24
Change from baseline in Alzheimers Disease Assessment Scale-cognitive subscale 11-item (ADAS-cog-11)
Time frame: Baseline and Week 24
Change from baseline in Mini-Mental State Examination (MMSE)
Time frame: Baseline and Week 24
Change from baseline in Neuropsychiatric Inventory (NPI)
Time frame: Baseline and Week 24
Change from baseline in Modified Crichton Scale
Time frame: Baseline and Week 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.